Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to meet 2027 goals.

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an investment analysis.

Sarepta Therapeutics (NASDAQ:SRPT) surges 40% post-market after strategic restructuring, workforce cuts, pipeline focus, and $400M cost-saving plans. Read more here.

Sarepta’s Elevidys will remain on the market with a black box warning. But this gene therapy for Duchenne muscular dystrophy still faces commercial headwinds and analysts say the company has ...

The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene therapy for Duchenne muscular dystrophy.

Sarepta Therapeutics stock (NASDAQ: SRPT) experienced a significant turnaround on Wednesday, with shares rising 33% in after-hours trading following the announcement of an extensive restructuring ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan designed ...

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a strategic restructuring and cost-cutting measures. What To Know: After ...

Sarepta's stock is jumping Thursday morning after the company announced a restructuring plan. Thomas Fuller / SOPA Images / LightRocket via Getty Images ...

Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label – After strategic review ...

The manufacturing-related rejection also delays a key test of the new FDA leadership’s support for cell and gene therapy against rare diseases.